2. Metabolic Enzyme/Protease Apoptosis Immunology/Inflammation
  3. Indoleamine 2,3-Dioxygenase (IDO) TNF Receptor Interleukin Related
  4. IDO1/TDO-IN-12

IDO1/TDO-IN-12 is an IDO1/TDO2 inhibitor with IC50 values of 0.825 and 4.04 μM, respectively. IDO1/TDO-IN-12 interacts with the ferrous heme cofactor in IDO1 as a non-competitive tryptophan inhibitor. IDO1/TDO-IN-12 inhibits nitric oxide production in LPS (HY-D1056)-stimulated immune cells. IDO1/TDO-IN-12 relieves pulmonary edema and lung injury in LPS-induced mouse models. IDO1/TDO-IN-12 can be used for the research of acute lung injury (ALI).

For research use only. We do not sell to patients.

IDO1/TDO-IN-12

IDO1/TDO-IN-12 Chemical Structure

CAS No. : 2841468-09-3

Size Stock
50 mg   Get quote  
100 mg   Get quote  
250 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

IDO1/TDO-IN-12 Related Antibodies

Top Publications Citing Use of Products

View All Indoleamine 2,3-Dioxygenase (IDO) Isoform Specific Products:

View All Isoforms
IDO1 IDO2 IDO

View All TNF Receptor Isoform Specific Products:

View All Isoforms
TNFRSF1A/CD120a TNFRSF3/CD18 TNFRSF4 TNFRSF5/CD40 TNFRSF6/Fas/CD95 TNFRSF7/CD27 TNFRSF8/CD30 TNFRSF9/4-1BB/CD137 TNFRSF10B/DR5/CD262 TNFRSF12A/TWEAK TNFRSF16/NGF Receptor/CD271 TNFRSF18/GITR/CD357

View All Interleukin Related Isoform Specific Products:

View All Isoforms
IL-1 IL-2 IL-3 IL-4 IL-5 IL-6 IL-8 IL-10 IL-12 IL-13 IL-15 IL-17 IL-23 IL-7 IL-33 IL-22 IL-18

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

IDO1/TDO-IN-12 is an IDO1/TDO2 inhibitor with IC50 values of 0.825 and 4.04 μM, respectively. IDO1/TDO-IN-12 interacts with the ferrous heme cofactor in IDO1 as a non-competitive tryptophan inhibitor. IDO1/TDO-IN-12 inhibits nitric oxide production in LPS (HY-D1056)-stimulated immune cells. IDO1/TDO-IN-12 relieves pulmonary edema and lung injury in LPS-induced mouse models. IDO1/TDO-IN-12 can be used for the research of acute lung injury (ALI)[1].

IC50 & Target[1]

IDO1

0.825 μM (IC50)

TNF-α

 

IL-1β

 

In Vitro

IDO1/TDO-IN-12 (compound 22) (48 h) inhibits IDO1 activity in IFN-γ-stimulated BxPC-3 cells with an IC50 of 0.854 μM[1].
IDO1/TDO-IN-12 (0.05-5.0 μM; 48 h) inhibits LPS-induced NO production in RAW264.7 cells in a concentration-dependent manner, with 31.3%, 40.2%, and 78.1% inhibition at 0.05, 0.5, and 5.0 μM, respectively[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

IDO1/TDO-IN-12 Related Antibodies
In Vivo

IDO1/TDO-IN-12 (compound 22) (15-100 mg/kg; i.p.; two doses; 0.5 h pre-LPS and 12 h post-LPS) protects against LPS-induced inflammatory
response and lung injury in a mouse model of ALI[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: BALB/c mice (male, 8 weeks old) with LPS-induced acute lung injury)[1]
Dosage: 15; 50; 100 mg/kg
Administration: i.p.; two doses; 0.5 h pre-LPS and 12 h post-LPS
Result: Significantly reduced pulmonary edema (lung wet/dry ratio) compared to LPS-only group, with no dose-dependent reduction observed.
Reduced lung tissue levels of TNF-α and IL-1β in a dose-dependent manner.
Protected against lung injury in a dose-dependent manner based on H&E staining lung injury scoring.
Reduced lung tissue expression of myeloperoxidase (MPO) and citrullinated histone H3 (CitH3) in a dose-dependent manner.
Caused no significant changes in mouse body weight across any treatment groups.
Molecular Weight

523.93

Formula

C19H17ClF3N3O5S2
CAS No.
SMILES

O=C(C1=CC2=C(OC(S(CC3=CC=C(C=C3)Cl)=O)=N2)C=C1)NCCCNS(=O)(C(F)(F)F)=O
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

IDO1/TDO-IN-12 Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

IDO1/TDO-IN-122841468-09-3Indoleamine 2,3-Dioxygenase (IDO)TNF ReceptorInterleukin RelatedTumor Necrosis Factor ReceptorTNFRILlung injuryTDO2nitric oxideRAW264.7 cellstryptophanferrous heme cofactorIDO1pulmonary edemaLPS-stimulated immune cellsBxPC-3 cellsInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
IDO1/TDO-IN-12
Cat. No.:
HY-184027
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.